S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
How major US stock indexes fared Friday 6/2/2023
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
How major US stock indexes fared Friday 6/2/2023
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
How major US stock indexes fared Friday 6/2/2023
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
What Should Investors Make of These 3 Dividend Cuts?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Trading Channel Breakout in Lululemon Brought by Earnings
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Constellation Brands Taps into Growth: Analysts Bullish on Stock
Salesforce: Time to Snap it Up as the Market Buys the Dip?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
How major US stock indexes fared Friday 6/2/2023
NASDAQ:RKDA

Arcadia Biosciences (RKDA) Stock Forecast, Price & News

$4.82
+0.12 (+2.55%)
(As of 06/2/2023 ET)
Compare
Today's Range
$4.80
$4.86
50-Day Range
$4.21
$7.87
52-Week Range
$4.18
$54.00
Volume
4,291 shs
Average Volume
37,298 shs
Market Capitalization
$4.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

Arcadia Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
294.2% Upside
$19.00 Price Target
Short Interest
Healthy
2.08% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.56mentions of Arcadia Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$21,550 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($18.44) to ($6.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars


RKDA stock logo

About Arcadia Biosciences (NASDAQ:RKDA) Stock

Arcadia Biosciences, Inc. is an agricultural biotechnology company, which engages in the development of agricultural products. It uses screening, breeding, and biotechnology techniques to create agricultural products for consumers, processors, and farmers. Its products include GoodWheat pasta, Zola coconut water, ProVault topical pain relief, and SoulSpring bath and body care. The company was founded by Eric J. Rey and John G. Sperling in 2002 and is headquartered in Davis, CA.

Receive RKDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcadia Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RKDA Stock News Headlines

Wall Street Legend Who Called AMZN Crash Issues New Sell Alert
Now, after years of big gains, he says one popular company's day in the sun is finally coming to an end. You must get off this sinking ship – NOW. 1 million people follow him for his surprisingly accurate predictions. His new sell alert could save your wealth in 2023.
8-K: Arcadia Biosciences, Inc.
Q1 2023 Arcadia Biosciences Inc Earnings Call
Arcadia Biosciences reports Q1 results
Arcadia Biosciences (RKDA) to Release Earnings on Thursday
Wall Street Legend Who Called AMZN Crash Issues New Sell Alert
Now, after years of big gains, he says one popular company's day in the sun is finally coming to an end. You must get off this sinking ship – NOW. 1 million people follow him for his surprisingly accurate predictions. His new sell alert could save your wealth in 2023.
Earnings Preview For Arcadia Biosciences
See More Headlines

RKDA Price History

RKDA Company Calendar

Last Earnings
3/30/2023
Today
6/03/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Agricultural production - crops
Sub-Industry
N/A
Current Symbol
NASDAQ:RKDA
Employees
58
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+294.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-15,380,000.00
Net Margins
-245.87%
Pretax Margin
-247.08%

Debt

Sales & Book Value

Annual Sales
$9.96 million
Book Value
$19.46 per share

Miscellaneous

Free Float
841,000
Market Cap
$4.15 million
Optionable
Not Optionable
Beta
0.98

Key Executives

  • Stanley E. Jacot
    President, Chief Executive Officer & Director
  • Belinda Yao
    Vice President-Operations
  • Thomas J. Schaefer
    Chief Financial Officer
  • Brett Michel
    General Manager
  • Laura Pitlik
    Chief Marketing Officer













RKDA Stock - Frequently Asked Questions

Should I buy or sell Arcadia Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RKDA shares.
View RKDA analyst ratings
or view top-rated stocks.

What is Arcadia Biosciences' stock price forecast for 2023?

1 Wall Street research analysts have issued 1 year price targets for Arcadia Biosciences' shares. Their RKDA share price forecasts range from $18.00 to $20.00. On average, they expect the company's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 294.2% from the stock's current price.
View analysts price targets for RKDA
or view top-rated stocks among Wall Street analysts.

How have RKDA shares performed in 2023?

Arcadia Biosciences' stock was trading at $0.2710 at the beginning of 2023. Since then, RKDA shares have increased by 1,678.6% and is now trading at $4.82.
View the best growth stocks for 2023 here
.

Are investors shorting Arcadia Biosciences?

Arcadia Biosciences saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 12,400 shares, a decrease of 69.8% from the April 30th total of 41,000 shares. Based on an average daily volume of 167,500 shares, the days-to-cover ratio is presently 0.1 days. Currently, 2.1% of the shares of the stock are sold short.
View Arcadia Biosciences' Short Interest
.

When is Arcadia Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our RKDA earnings forecast
.

How were Arcadia Biosciences' earnings last quarter?

Arcadia Biosciences, Inc. (NASDAQ:RKDA) announced its earnings results on Thursday, March, 30th. The basic materials company reported ($6.31) earnings per share (EPS) for the quarter. The basic materials company had revenue of $1 million for the quarter. Arcadia Biosciences had a negative trailing twelve-month return on equity of 63.53% and a negative net margin of 245.87%.

When did Arcadia Biosciences' stock split?

Arcadia Biosciences's stock reverse split on the morning of Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Matthew Plavan's approval rating as Arcadia Biosciences' CEO?

1 employees have rated Arcadia Biosciences Chief Executive Officer Matthew Plavan on Glassdoor.com. Matthew Plavan has an approval rating of -100% among the company's employees. This puts Matthew Plavan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arcadia Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Bionano Genomics (BNGO), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI), Novan (NOVN), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF).

When did Arcadia Biosciences IPO?

(RKDA) raised $66 million in an initial public offering (IPO) on Friday, May 15th 2015. The company issued 8,200,000 shares at $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO.

What is Arcadia Biosciences' stock symbol?

Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA."

Who are Arcadia Biosciences' major shareholders?

Arcadia Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (9.62%), Sabby Management LLC (6.16%), State Street Corp (1.42%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Pamela Haley, Stanley Jacot Jr and Thomas J Schaefer.
View institutional ownership trends
.

How do I buy shares of Arcadia Biosciences?

Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcadia Biosciences' stock price today?

One share of RKDA stock can currently be purchased for approximately $4.82.

How much money does Arcadia Biosciences make?

Arcadia Biosciences (NASDAQ:RKDA) has a market capitalization of $4.15 million and generates $9.96 million in revenue each year. The basic materials company earns $-15,380,000.00 in net income (profit) each year or ($28.77) on an earnings per share basis.

How can I contact Arcadia Biosciences?

Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The official website for the company is www.arcadiabio.com. The basic materials company can be reached via phone at (530) 756-7077, via email at ir@arcadiabio.com, or via fax at 530-756-7027.

This page (NASDAQ:RKDA) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -